Scientists at Florida International University have developed a promising new compound that could slow the progression of ...

Research from FIU scientists have discovered a promising new compound that could slow the progression of Parkinson's disease ...

Many terms have been invented to describe different types of hallucinogenic drugs, sometimes based on an analogy with the ...

For decades, treatment of Parkinson’s disease has centered on replacing dopamine, the neurotransmitter whose decline drives ...

Aspen's sasineprocel is an autologous induced pluripotent stem cell (iPSC) derived dopaminergic neuron precursor cell (DANPC) ...

Sasineprocel’s encouraging Phase I/IIa data positions autologous iPSC-derived dopaminergic neuron therapy as a potential monotherapy challenger in Parkinson’s disease (PD), signaling a shift toward ...

The firm intends to launch the trial based on positive results from an open-label Phase I/IIa trial of sasineprocel, previously known as ANPD001.

New carbidopa/levodopa labels will state that seizures linked to vitamin B6 deficiency can ...

FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo March 20 (Reuters) - The U.S.

These results represent a 74.27% shortfall in revenue. In addition, Arvinas will present Phase 1 clinical trial data for ARV-102 in Parkinson’s disease patients at the 2026 International Conference on ...